Lake Street lowered the firm’s price target on OptimizeRx (OPRX) to $11 from $15 and keeps a Buy rating on the shares. Revenue came in roughly $3.7M short of the $25.0M consensus, mainly due to a shortfall in the DTC Medicx business, the analyst tells investors. The company is implementing changes to its 2025 plan with greater focus on self-serve, which should alleviate some of the softness in the DTC business, but the company lowered its 2024 outlook to account for the change, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target lowered to $16 from $20 at Roth MKM
- OptimizeRx price target lowered to $8 from $16 at JMP Securities
- OptimizeRx price target lowered to $5 from $11 at Barclays
- OptimizeRx Reports Strong Revenue Growth in Q3 2024
- Closing Bell Movers: Tetra Tech down 8% after Q4 results, guidance